Investor Sues Immunomedics Over Cancer Drug Misstatements
An investor for clinical-stage biopharmaceutical company Immunomedics Inc. on Thursday filed a putative class action against the company, alleging that misstatements about its eligibility to present research about trials for a...To view the full article, register now.
Already a subscriber? Click here to view full article